254 related articles for article (PubMed ID: 1685125)
1. [3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues.
Johnson MP; Conarty PF; Nichols DE
Eur J Pharmacol; 1991 Jul; 200(1):9-16. PubMed ID: 1685125
[TBL] [Abstract][Full Text] [Related]
2. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain.
Steele TD; Nichols DE; Yim GK
Biochem Pharmacol; 1987 Jul; 36(14):2297-303. PubMed ID: 2886126
[TBL] [Abstract][Full Text] [Related]
3. 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine.
McKenna DJ; Guan XM; Shulgin AT
Pharmacol Biochem Behav; 1991 Mar; 38(3):505-12. PubMed ID: 1829838
[TBL] [Abstract][Full Text] [Related]
4. Behavioral, biochemical and neurotoxicological actions of the alpha-ethyl homologue of p-chloroamphetamine.
Johnson MP; Huang XM; Oberlender R; Nash JF; Nichols DE
Eur J Pharmacol; 1990 Nov; 191(1):1-10. PubMed ID: 1982656
[TBL] [Abstract][Full Text] [Related]
5. Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan.
Marona-Lewicka D; Nichols DE
Eur J Pharmacol; 1994 Jun; 258(1-2):1-13. PubMed ID: 7925587
[TBL] [Abstract][Full Text] [Related]
6. p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent.
Huang X; Marona-Lewicka D; Nichols DE
Eur J Pharmacol; 1992 Dec; 229(1):31-8. PubMed ID: 1473561
[TBL] [Abstract][Full Text] [Related]
7. Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine.
Crespi D; Mennini T; Gobbi M
Br J Pharmacol; 1997 Aug; 121(8):1735-43. PubMed ID: 9283711
[TBL] [Abstract][Full Text] [Related]
8. 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents.
Hekmatpanah CR; Peroutka SJ
Eur J Pharmacol; 1990 Feb; 177(1-2):95-8. PubMed ID: 1971219
[TBL] [Abstract][Full Text] [Related]
9. Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists.
Callaway CW; Johnson MP; Gold LH; Nichols DE; Geyer MA
Psychopharmacology (Berl); 1991; 104(3):293-301. PubMed ID: 1924637
[TBL] [Abstract][Full Text] [Related]
10. Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors.
Nash JF; Brodkin J
J Pharmacol Exp Ther; 1991 Nov; 259(2):820-5. PubMed ID: 1682486
[TBL] [Abstract][Full Text] [Related]
11. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine.
Berger UV; Gu XF; Azmitia EC
Eur J Pharmacol; 1992 May; 215(2-3):153-60. PubMed ID: 1356787
[TBL] [Abstract][Full Text] [Related]
12. (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity.
Oberlender R; Nichols DE
J Pharmacol Exp Ther; 1990 Dec; 255(3):1098-106. PubMed ID: 1979813
[TBL] [Abstract][Full Text] [Related]
13. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy').
Baumann MH; Clark RD; Budzynski AG; Partilla JS; Blough BE; Rothman RB
Neuropsychopharmacology; 2005 Mar; 30(3):550-60. PubMed ID: 15496938
[TBL] [Abstract][Full Text] [Related]
14. Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices.
Johnson MP; Hoffman AJ; Nichols DE
Eur J Pharmacol; 1986 Dec; 132(2-3):269-76. PubMed ID: 2880735
[TBL] [Abstract][Full Text] [Related]
15. Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat.
O'Loinsigh ED; Boland G; Kelly JP; O'Boyle KM
Prog Neuropsychopharmacol Biol Psychiatry; 2001 Apr; 25(3):621-38. PubMed ID: 11371001
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of dopamine release by methylenedioxymethamphetamine is mediated by serotonin.
Gazzara RA; Takeda H; Cho AK; Howard SG
Eur J Pharmacol; 1989 Sep; 168(2):209-17. PubMed ID: 2575036
[TBL] [Abstract][Full Text] [Related]
17. Psychostimulant-like effects of p-fluoroamphetamine in the rat.
Marona-Lewicka D; Rhee GS; Sprague JE; Nichols DE
Eur J Pharmacol; 1995 Dec; 287(2):105-13. PubMed ID: 8749023
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain.
Schmidt CJ; Levin JA; Lovenberg W
Biochem Pharmacol; 1987 Mar; 36(5):747-55. PubMed ID: 2881549
[TBL] [Abstract][Full Text] [Related]
19. Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue.
Johnson MP; Huang XM; Nichols DE
Pharmacol Biochem Behav; 1991 Dec; 40(4):915-22. PubMed ID: 1726189
[TBL] [Abstract][Full Text] [Related]
20. Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices.
Fitzgerald JL; Reid JJ
Naunyn Schmiedebergs Arch Pharmacol; 1993 Mar; 347(3):313-23. PubMed ID: 8097569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
